Supernus to Host First Quarter 2021 Financial Results Conference Call

Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its Q1 2021 results on May 5, 2021, after market close. The conference call, led by CEO Jack Khattar and CFO Jim Kelly, is scheduled for 4:30 p.m. ET that day, with a live webcast available on the company’s website. Supernus specializes in CNS diseases, offering treatments for several conditions, including epilepsy and ADHD. The company is also developing new products aimed at various CNS disorders. Further details can be found in the Investor Relations section of their website.

Positive

• Strong focus on CNS disease treatments with an expanding portfolio.
• Development of novel product candidates targeting various CNS disorders.

Negative

• None.

ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the first quarter of 2021 after the market closes on Wednesday, May 5, 2021.

Jack Khattar, President and CEO, and Jim Kelly, Executive Vice President and CFO, will host a conference call to present the first quarter 2021 financial and business results on Wednesday, May 5, 2021 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:	(877) 288-1043
International dial-in:	(970) 315-0267
Conference ID:	9275942
Conference Call Name:	Supernus Pharmaceuticals First Quarter 2021 Results Conference Call

Following the live call, a replay will be available on the Company’s website, www.supernus.com, under the Investor Relations section. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders. For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and Chief Executive Officer
Jim Kelly, EVP & Chief Financial Officer
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
Westwicke/ICR
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com

FAQ

When will Supernus Pharmaceuticals announce its Q1 2021 results?

Supernus Pharmaceuticals will report its Q1 2021 results on May 5, 2021, after market close.

What time is the Supernus Pharmaceuticals conference call for Q1 2021 results?

The Supernus Pharmaceuticals conference call for Q1 2021 results is scheduled for 4:30 p.m. ET on May 5, 2021.

How can I access the Supernus Pharmaceuticals Q1 2021 results conference call?

The Q1 2021 results conference call can be accessed via a live webcast on Supernus Pharmaceuticals' website.

What therapeutic areas does Supernus Pharmaceuticals focus on?

Supernus Pharmaceuticals focuses on developing treatments for central nervous system (CNS) diseases, including epilepsy, ADHD, and Parkinson's disease.